| 1. |
- Jiang, Sheng, et al.
(författare)
-
Constructing Chromium Multioxide Hole-Selective Heterojunction for High-Performance Perovskite Solar Cells
- 2022
-
Ingår i: Advanced Science. - : Wiley. - 2198-3844. ; 9:30
-
Tidskriftsartikel (refereegranskat)abstract
- Perovskite solar cells (PSCs) suffer from significant nonradiative recombination at perovskite/charge transport layer heterojunction, seriously limiting their power conversion efficiencies. Herein, solution-processed chromium multioxide (CrOx) is judiciously selected to construct a MAPbI(3)/CrOx/Spiro-OMeTAD hole-selective heterojunction. It is demonstrated that the inserted CrOx not only effectively reduces defect sites via redox shuttle at perovskite contact, but also decreases valence band maximum (VBM)-HOMO offset between perovskite and Spiro-OMeTAD. This will diminish thermionic losses for collecting holes and thus promote charge transport across the heterojunction, suppressing both defect-assisted recombination and interface carrier recombination. As a result, a remarkable improvement of 21.21% efficiency with excellent device stability is achieved compared to 18.46% of the control device, which is among the highest efficiencies for polycrystalline MAPbI(3) based n-i-p planar PSCs reported to date. These findings of this work provide new insights into novel charge-selective heterojunctions for further enhancing efficiency and stability of PSCs.
|
|
| 2. |
- Lensink, Marc F., et al.
(författare)
-
Impact of AlphaFold on structure prediction of protein complexes: The CASP15-CAPRI experiment
- 2023
-
Ingår i: Proteins. - : WILEY. - 0887-3585 .- 1097-0134.
-
Tidskriftsartikel (refereegranskat)abstract
- We present the results for CAPRI Round 54, the 5th joint CASP-CAPRI protein assembly prediction challenge. The Round offered 37 targets, including 14 homodimers, 3 homo-trimers, 13 heterodimers including 3 antibody-antigen complexes, and 7 large assemblies. On average similar to 70 CASP and CAPRI predictor groups, including more than 20 automatics servers, submitted models for each target. A total of 21 941 models submitted by these groups and by 15 CAPRI scorer groups were evaluated using the CAPRI model quality measures and the DockQ score consolidating these measures. The prediction performance was quantified by a weighted score based on the number of models of acceptable quality or higher submitted by each group among their five best models. Results show substantial progress achieved across a significant fraction of the 60+ participating groups. High-quality models were produced for about 40% of the targets compared to 8% two years earlier. This remarkable improvement is due to the wide use of the AlphaFold2 and AlphaFold2-Multimer software and the confidence metrics they provide. Notably, expanded sampling of candidate solutions by manipulating these deep learning inference engines, enriching multiple sequence alignments, or integration of advanced modeling tools, enabled top performing groups to exceed the performance of a standard AlphaFold2-Multimer version used as a yard stick. This notwithstanding, performance remained poor for complexes with antibodies and nanobodies, where evolutionary relationships between the binding partners are lacking, and for complexes featuring conformational flexibility, clearly indicating that the prediction of protein complexes remains a challenging problem.
|
|
| 3. |
- Wei, Qichun, et al.
(författare)
-
EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases
- 2007
-
Ingår i: International Journal of Oncology. - 1019-6439 .- 1791-2423. ; 31:3, s. 493-499
-
Tidskriftsartikel (refereegranskat)abstract
- The expression of EGFR, HER2 and HER3 receptors were analyzed in immunohistochemical preparations from primary esophageal tumours and corresponding lymph node metastases. The goal was to evaluate whether any of these receptors are suitable as targets for radionuclide based imaging and therapy. The receptor expressions were evaluated in parallel samples, primary tumour and metastasiis, from each patient (n = 51). The majority of the cases were esophageal squamous cell carcinomas, ESCC, (n = 40). The HercepTest scoring was used for the analysis of both HER2 and EGFR expression (0, 1+, 2+ or 3+). HER3 was only evaluated as negative, weak or strong staining. EGFR overexpression (2+/3+) was found in 67.5 % (27/40) of both the ESCC primary tumours and the corresponding lymph node metastases. There were only a few changes in these EGFR-scores;: two cases from 2+/3+ to 0/1+ when the primary tumours were compared to the corresponding metastases and two changes the other way around. HER2 overexpression (2+/3+) was only found only in 3three of the primary ESCC tumours and 2two of the lymph node metastases. EGFR and HER2 stainings were found mainly in the cell membranes. The HER3 staining (weak or strong) was mainly cytoplasmic and granular and was observed in about half (20/39) of the cases, for both the ESCC primary tumours and the corresponding lymph node metastases. It is was concluded that ESCC lymph node metastases generally have a strong expression of EGFR stronglyin their cell membranes and to the same extent as in the primary tumours. The stability in EGFR expression is encouraging for efforts to develop radionuclide based EGFR imaging agents. It is also possible that EGFR targeting agents (e.g. Iressa, Tarceva, Erbitux or radiolabelled antibodies) can be applied for therapy of ESCC.
|
|
| 4. |
- Wei, Qichun, et al.
(författare)
-
EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases
- 2008
-
Ingår i: Annals of Surgical Oncology. - : Springer Science and Business Media LLC. - 1068-9265 .- 1534-4681. ; 15:4, s. 1193-1201
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: There are several substances available to target members of the epidermal growth factor receptor (EGFR) family, both for imaging in nuclear medicine and for various forms of therapy. The level and stability of expression in both primary tumors and corresponding metastases is crucial in the assessment of a receptor as a target in systemic tumor therapy. To date, the expression of EGFR family members has only been determined in primary laryngeal carcinomas, and we have not found published data regarding the receptor status in corresponding metastatic lesions. METHODS: Expression of EGFR, HER2, and HER3 was investigated immunohistochemically in both lymph node metastases and corresponding primary laryngeal squamous carcinomas (n = 40). RESULTS: EGFR overexpression (2+ or 3+) was found in 87.5% (35/40) of the laryngeal primary tumors and 82.5% (33/40) of the corresponding lymph node metastases. There was a good agreement between the primary tumors and the paired metastases regarding EGFR expression. HER2 overexpression was found in only four cases (10.5%) of the studied primary tumors and in all cases the HER2 expression was retained in the paired metastases. Another two metastases gained HER2 status when compared to the corresponding primary tumors. Strong HER3 staining was found in 26.7% of both the primary tumors and the corresponding metastases. CONCLUSIONS: The high frequency and stability in EGFR expression is encouraging for efforts to use EGFR targeting agents (e.g. Iressa, Tarceva, Erbitux or radiolabeled antibodies) for therapy of laryngeal carcinoma. For a few laryngeal carcinoma patients with HER2 overexpression, anti-HER2 agents could possibly be used.
|
|
| 5. |
- Xiong, Shaobing, et al.
(författare)
-
Revealing buried heterointerface energetics towards highly efficient perovskite solar cells
- 2023
-
Ingår i: Nano Energy. - : ELSEVIER. - 2211-2855 .- 2211-3282. ; 109
-
Tidskriftsartikel (refereegranskat)abstract
- The heterointerfaces of charge-selective contacts are crucial in determining efficiency and stability of perovskite optoelectronic devices, where the fundamental knowledge of the buried heterointerface between perovskite and bottom charge transport layer is less well understood compared to the top interface. Herein, we systematically investigate the energetics at the perovskite/SnO2 buried heterointerface for an n-i-p perovskite solar cell (PSC) and the perovskite/PEDOT:PSS buried heterointerface for a p-i-n one, respectively. In contrast to previous cognitions, we discover a perovskite transition phase at the buried interface region that originates from the chemical bonding interaction with the bottom charge transport layer. The transition phase causes an energy level barrier and induces defects, impeding charge transport across the heterointerface. These detrimental effects trigger significant nonradiative recombination and limit the attainable device photovoltage. We then develop the energetic models that describe such buried heterointerfaces. Moreover, we further test the proposed model -derived mechanisms via inserting a thin polyvinyl alcohol layer into the buried heterointerfaces of the de-vices. We demonstrate that chemical interactions and formation of the perovskite transition phase at the buried heterointerface thereby are fully restrained, leading to a diminished electron extraction barrier and improved charge transport. As a result, significant increases in open-circuit voltage and fill factor of the devices are ach-ieved. These results will help guide future efforts on developing suitable buried heterointerfaces for superior performance of perovskite optoelectronics.
|
|
